P-1435. Effectiveness of RSV Immunization among Infants in Their First RSV Season in the United States, 2023-2024 and 2024-2025 Seasons

Open Forum Infectious Diseases 2026 Open access

Read full text
Authors: Amanda B Payne, Steph Battan-Wraith, Sarah E. Reese, Cassandra A. Hathaway, Sara Yee Tartof, Karthik V. Natarajan, Stephanie Irving, Shaun J. Grannis, Sean Chickery, Gabriela X. Vazquez-Benitez, Kristin K. Dascomb, S Bianca Salas
+25 more Cassandra Bezi, Lina S. Sy, Bruno Lewin, Melissa S Stockwell, Ashley B. Stephens, Jungmi Han, Allison L. Naleway, Brian E Dixon, Colin M. Rogerson, Thomas J. Duszynski, William F. Fadel, Sarah W. Ball, Jingran Cao, Charlene E McEvoy, Tamara Sheffield, Daniel L. Bride, Julie Arndorfer, Joshua Van Otterloo, Amber Kautz, Allison Avrich Ciesla, Morgan Najdowski, Josephine Mak, Jennifer DeCuir, Ryan E Wiegand, Ruth Link-Gelles
DOI: 10.1093/ofid/ofaf695.1622
Cited by: 1

Abstract

Abstract Background During the 2023-2024 and 2024-2025 respiratory virus seasons, two products, a maternal vaccine (Abrysvo, by Pfizer) and an infant monoclonal antibody (nirsevimab), were recommended in the United States to protect infants against severe respiratory syncytial virus (RSV) disease during their first RSV season. We estimated product effectiveness (PE) against RSV-associated emergency department (ED) encounters and hospitalizations among infants in their first RSV season during these seasons.Table 1.Nirsevimab effectiveness against RSV-associated ED encounters and hospitalization among infants in their first RSV season, VISION, 2023-2024 and 2024-2025 RSV seasonsRSV = respiratory syncytial virus; ED = emergency department; IQR = interquartile range; CI = confidence interval; Ref = reference group; PE = product effectiveness; VISION = Virtual SARS-CoV-2, Influenza, and Other respiratory viruses Network*Encounters included those among infants aged

Fields of Study & Subjects

Respiratory viral infections research COVID-19 Impact on Reproduction Pneumonia and Respiratory Infections

Publication details

Journal / source
Open Forum Infectious Diseases
Publisher
Oxford University Press (OUP)
Volume
13
Issue
Supplement_1
Publication date
1 January 2026
Language
EN